MedTrace Logo

A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema

NCT00676884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2008-05-13

No results posted yet for this study

Summary

The primary objective of this study is to investigate the effect of AERODERM (also known as pitrakinra, AER 001, BAY 16-9996) on Eczema Area and Severity Index (EASI) score in subjects with moderate to severe atopic eczema

Conditions

  • Atopic Eczema

Interventions

DRUG

Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)

30 mgs s.c. b.i.d.

DRUG

placebo

1.5 mL s.c. b.i.d.

Sponsors & Collaborators

  • Aerovance, Inc.

    lead INDUSTRY

Principal Investigators

  • Darren Wilbraham, MBBS · Guy's Drug Research Unit, Quintiles Limited

  • Richard Groves, FRCP · St. Johns Institute of Dermatology St. Thomas' Hospital London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-07-31
Completion
2006-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676884 on ClinicalTrials.gov